Cargando…

Impact of abiraterone acetate plus prednisone or enzalutamide on fatigue and cognition in patients with metastatic castration-resistant prostate cancer: initial results from the observational AQUARiUS study

INTRODUCTION: Abiraterone acetate plus prednisone (AAP) and enzalutamide (ENZ) are commonly prescribed for metastatic castration-resistant prostate cancer (mCRPC). Data comparing their effects on patient-reported outcomes (PROs) from routine clinical practice are limited. METHODS: AQUARiUS (NCT02813...

Descripción completa

Detalles Bibliográficos
Autores principales:	Thiery-Vuillemin, Antoine, Hvid Poulsen, Mads, Lagneau, Edouard, Ploussard, Guillaume, Birtle, Alison, Dourthe, Louis-Marie, Beal-Ardisson, Dominique, Pintus, Elias, Trepiakas, Redas, Antoni, Laurent, Lukac, Martin, Van Sanden, Suzy, Pissart, Geneviève, Reid, Alison
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2018
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6088345/ https://www.ncbi.nlm.nih.gov/pubmed/30116592 http://dx.doi.org/10.1136/esmoopen-2018-000397

Ejemplares similares

Abiraterone acetate plus prednisone for the Management of Metastatic Castration-Resistant Prostate Cancer (mCRPC) without prior use of chemotherapy: report from a large, international, real-world retrospective cohort study
por: Boegemann, Martin, et al.
Publicado: (2019)

Observational study on time on treatment with abiraterone and enzalutamide
por: Fallara, Giuseppe, et al.
Publicado: (2020)

Abiraterone In Vitro Is Superior to Enzalutamide in Response to Ionizing Radiation
por: Wright, Timothy C., et al.
Publicado: (2021)

Abiraterone, Orteronel, Enzalutamide and Docetaxel: Sequential or Combined Therapy?
por: Chen, Ming-kun, et al.
Publicado: (2022)

Oncoming tides in the Age(ing) of Aquarius
por: Frost, David W, et al.
Publicado: (2009)

Plasma AR Copy Number Changes and Outcome to Abiraterone and Enzalutamide
por: Gurioli, Giorgia, et al.
Publicado: (2020)

Real‑world survival outcome comparing abiraterone acetate plus prednisone and enzalutamide for nonmetastatic castration‐resistant prostate cancer
por: Tsujino, Takuya, et al.
Publicado: (2023)

Cardiovascular toxicities associated with abiraterone compared to enzalutamide–A pharmacovigilance study
por: Cone, Eugene B., et al.
Publicado: (2021)

Economic Outcomes in Patients with Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide or Abiraterone Acetate Plus Prednisone
por: Ramaswamy, Krishnan, et al.
Publicado: (2020)

Survival of veterans treated with enzalutamide and abiraterone for metastatic castrate resistant prostate cancer based on comorbid diseases
por: Schoen, Martin W., et al.
Publicado: (2022)

Docetaxel, abiraterone, enzalutamide, apalutamide in patients with metastatic hormone-sensitive prostate cancer
por: Talwar, Harkirat Singh
Publicado: (2021)

Outcomes Following Abiraterone versus Enzalutamide for Prostate Cancer: A Scoping Review
por: Shah, Yash B., et al.
Publicado: (2022)

Real-World Safety and Efficacy Outcomes with Abiraterone Acetate Plus Prednisone or Prednisolone as the First- or Second-Line Treatment for Metastatic Castration-Resistant Prostate Cancer: Data from the Prostate Cancer Registry
por: Bjartell, Anders, et al.
Publicado: (2021)

Abiraterone Alone or in Combination With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer With Rising Prostate-Specific Antigen During Enzalutamide Treatment
por: Attard, Gerhardt, et al.
Publicado: (2018)

The complete mitochondrial genome sequence of Aquarius elongatus (Hemiptera: Gerridae)
por: Cui, Ying, et al.
Publicado: (2021)

Correction to: Survival of veterans treated with enzalutamide and abiraterone for metastatic castrate resistant prostate cancer based on comorbid diseases
por: Schoen, Martin W., et al.
Publicado: (2023)

Concurrent or layered treatment with radium-223 and enzalutamide or abiraterone/prednisone: real-world clinical outcomes in patients with metastatic castration-resistant prostate cancer
por: Shore, Neal, et al.
Publicado: (2020)

Response to flutamide, as second-line therapy after bicalutamide, predicts efficacy of abiraterone, not that of enzalutamide
por: Nakai, Yasushi, et al.
Publicado: (2018)

Risk for stroke and myocardial infarction with abiraterone versus enzalutamide in metastatic prostate cancer patients
por: Kulkarni, A.A., et al.
Publicado: (2021)

Healthcare Costs for Metastatic Castration-Resistant Prostate Cancer Patients Treated with Abiraterone or Enzalutamide
por: Rana, Dikshyanta, et al.
Publicado: (2021)

Comparative Effectiveness of Abiraterone and Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer in Taiwan
por: Li, Pei-Yu, et al.
Publicado: (2022)

Idarubicin combats abiraterone and enzalutamide resistance in prostate cells via targeting XPA protein
por: Zhang, Ying, et al.
Publicado: (2022)

Aquarius is required for proper CtIP expression and homologous recombination repair
por: Sakasai, Ryo, et al.
Publicado: (2017)

The Prostate Cancer Therapy Enzalutamide Compared with Abiraterone Acetate/Prednisone Impacts Motivation for Exploration, Spatial Learning and Alters Dopaminergic Transmission in Aged Castrated Mice
por: Nicola, Celeste, et al.
Publicado: (2021)

Genomic alterations in plasma DNA from patients with metastasized prostate cancer receiving abiraterone or enzalutamide
por: Belic, Jelena, et al.
Publicado: (2018)

Physician Dispensing Among Urology Practices and the Use of Abiraterone or Enzalutamide for Men With Advanced Prostate Cancer
por: Lai, Lillian Y, et al.
Publicado: (2022)

Comparison of real-life data of abiraterone acetate and enzalutamide in metastatic castration-resistant prostate cancer
por: Demirci, Ayşe, et al.
Publicado: (2021)

Management of prostate cancer by targeting 3βHSD1 after enzalutamide and abiraterone treatment
por: Mei, Zejie, et al.
Publicado: (2022)

A scoping review protocol to elucidate outcomes following abiraterone versus enzalutamide for prostate cancer
por: Shah, Yash B., et al.
Publicado: (2022)

Predicting response to enzalutamide and abiraterone in metastatic prostate cancer using whole-omics machine learning
por: de Jong, Anouk C., et al.
Publicado: (2023)

Clinical outcomes of volume of disease on patients receiving enzalutamide versus abiraterone acetate plus prednisone as first-line therapy for metastatic castration-resistant prostate cancer
por: Nuzzo, Pier Vitale, et al.
Publicado: (2023)

Activity of enzalutamide in men with metastatic castration resistant prostate cancer is affected by prior treatment with abiraterone and/or docetaxel
por: Cheng, Heather H., et al.
Publicado: (2015)

Treatment with abiraterone or enzalutamide does not impair immunological response to COVID-19 vaccination in prostate cancer patients
por: Liontos, Michalis, et al.
Publicado: (2021)

Survival by race in men with chemotherapy-naive enzalutamide- or abiraterone-treated metastatic castration-resistant prostate cancer
por: George, Daniel J., et al.
Publicado: (2021)

Mental health care utilization among men with castration‐resistant prostate cancer receiving abiraterone or enzalutamide
por: Tsao, Phoebe A., et al.
Publicado: (2023)

Causal inferences and real-world evidence: A comparative effectiveness evaluation of abiraterone acetate against enzalutamide
por: Johansson, Per, et al.
Publicado: (2023)

Corrigendum to Clinical outcomes of volume of disease on patients receiving enzalutamide vs. abiraterone acetate plus prednisone as first-line therapy for metastatic castration resistant prostate cancer
Publicado: (2023)

Abiraterone acetate plus Prednisone/Prednisolone compared with Enzalutamide in metastatic castration resistant prostate cancer before or after chemotherapy: A retrospective study of real‐world data (ACES)
por: Das, Prantik, et al.
Publicado: (2020)

Efficacy of Abiraterone and Enzalutamide in Pre- and Postdocetaxel Castration-Resistant Prostate Cancer: A Trial-Level Meta-Analysis
por: Fang, Mike, et al.
Publicado: (2017)

Higher Serum Testosterone Levels Associated with Favorable Prognosis in Enzalutamide- and Abiraterone-Treated Castration-Resistant Prostate Cancer
por: Sakamoto, Shinichi, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_l1l66q0ictk25cmpk47ccldi4a